---
layout: post
title: "Prospective Grant of an Exclusive Patent License: The Development of an in vivo Anti-CD19 Chimeric Antigen Receptor (CAR) for the Treatment of CD19-Expressing Human Cancers"
date: 2026-02-05 18:59:59 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-16056
original_published: 2022-07-27 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of an Exclusive Patent License: The Development of an in vivo Anti-CD19 Chimeric Antigen Receptor (CAR) for the Treatment of CD19-Expressing Human Cancers

**Published:** February 05, 2026 18:59 UTC
**Source:** Federal Register
**Original Published:** July 27, 2022 00:00 UTC
**Document Number:** 2022-16056

## Summary

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Capstan Therapeutics (Capstan), located in San Diego, California, the United States of America.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/07/27/2022-16056/prospective-grant-of-an-exclusive-patent-license-the-development-of-an-in-vivo-anti-cd19-chimeric)
- API: https://www.federalregister.gov/api/v1/documents/2022-16056

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
